Neurocrine Biosciences INC

Neurocrine Biosciences files an 8-K/A amendment to include audited and unaudited financial statements for Soleno Therapeutics and pro forma combined financial information following the acquisition.

Neurocrine Biosciences reported a 39% year-over-year revenue increase to $959 million for Q2 2026, driven by strong sales of INGREZZA and CRENESITY, and raised full-year INGREZZA guidance.

Neurocrine Biosciences stockholders approved the amendment of the 2025 Equity Incentive Plan and re-elected three Class III directors at the 2026 Annual Meeting.

Neurocrine Biosciences has finalized its acquisition of Soleno Therapeutics, adding VYKAT XR for Prader-Willi syndrome to its rare disease portfolio.

Neurocrine Biosciences reported a 44% year-over-year increase in Q1 2026 net product sales to $811 million, driven by INGREZZA and CRENESSITY, and announced a $2.9 billion acquisition of Soleno Therapeutics.

Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash to expand its rare disease and endocrinology portfolio.

Neurocrine Biosciences reported a significant increase in net income and revenue for the first quarter of 2026, driven by robust sales of INGREZZA and CRENESSITY, alongside progress in its development pipeline and a major acquisition.

Neurocrine Biosciences reports significant revenue growth driven by INGREZZA and CRENESSITY sales, alongside multiple pipeline advancements, despite increased operating expenses and a Phase 3 clinical trial setback.

Neurocrine Biosciences announced increased net product sales for the first half of 2025, driven by INGREZZA and the recent launch of CRENESSITY, despite higher operating expenses and a Phase 3 study setback for valbenazine in schizophrenia.

Neurocrine Biosciences' Q1 2025 results show revenue growth driven by INGREZZA sales, offset by increased R&D expenses and fluctuations in equity investments.

Neurocrine Biosciences reports a strong third quarter with increased product sales and pipeline advancements, while also announcing a CEO transition and share repurchase program.

Neurocrine Biosciences reports a significant increase in net product sales, driven by INGREZZA, and progresses its clinical programs in neurology and psychiatry.

Neurocrine Biosciences achieved significant revenue growth in 2025 driven by strong INGREZZA sales and the successful launch of CRENESSITY, while advancing a robust pipeline and navigating evolving regulatory landscapes.

Neurocrine Biosciences' 2024 10-K filing highlights strong INGREZZA sales, the launch of CRENESSITY, and progress across its neuropsychiatry and neurology pipeline.

Neurocrine Biosciences reports a strong financial year in 2023, driven by increased sales of INGREZZA and advancements in its clinical pipeline.

Leslie Norwalk V, a Director of Neurocrine Biosciences Inc, sold 1,250 shares of common stock on July 28, 2026 for $182.01 per share.

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences Inc, sold 4,367 shares of common stock on July 10, 2026 for $181.02 per share.

Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences Inc, sold 10,000 shares of common stock on July 9, 2026 for $179.60 per share.

Ingrid Delaet, Chief Regulatory Officer at Neurocrine Biosciences, executed a series of transactions involving the purchase and sale of company common stock, primarily under a Rule 10b5-1 trading plan.

Neurocrine Biosciences Chief Legal Officer Darin Lippoldt reported transactions involving the sale of company stock, executed under a pre-established Rule 10b5-1 trading plan.

Neurocrine Biosciences Director Stephen Sherwin exercised stock options and sold 25,000 shares under a 10b5-1 trading plan.

Neurocrine Biosciences, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for May 27, 2026, to vote on director elections, executive compensation, equity plan amendments, and auditor ratification.

Neurocrine Biosciences has filed a definitive proxy statement with the SEC, outlining information for an upcoming shareholder meeting.

Neurocrine Biosciences sets date for annual stockholder meeting on May 21, 2025, outlining key proposals including director elections and equity incentive plans.

Neurocrine Biosciences has filed a definitive proxy statement with the SEC.

Neurocrine Biosciences is holding its annual meeting on May 22, 2024, to vote on director elections, executive compensation, an equity incentive plan amendment, and auditor ratification.

JPMorgan Chase & Co. has filed a Schedule 13G, reporting beneficial ownership of 6.3% of Neurocrine Biosciences, Inc. common stock as of June 30, 2026.

Vanguard Capital Management has reported a beneficial ownership of 5.23% in Neurocrine Biosciences Inc. common stock as of March 31, 2026.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting zero beneficial ownership in Neurocrine Biosciences Inc. following an internal realignment.

JPMorgan Chase & Co. has reported a 5.2% beneficial ownership stake in Neurocrine Biosciences, Inc. common stock as of December 31, 2025.

Investment adviser Dodge & Cox has filed a Schedule 13G, revealing a 5.6% beneficial ownership stake in Neurocrine Biosciences, Inc. as of March 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 12.1% in Neurocrine Biosciences Inc.'s common stock as of March 31, 2025.